AXQ Capital LP Invests $290,000 in SiBone $SIBN

AXQ Capital LP acquired a new stake in shares of SiBone (NASDAQ:SIBN) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,390 shares of the company’s stock, valued at approximately $290,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Harbor Capital Advisors Inc. raised its stake in SiBone by 7.7% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 573,705 shares of the company’s stock valued at $10,797,000 after buying an additional 40,993 shares during the last quarter. Palumbo Wealth Management LLC purchased a new position in shares of SiBone in the 2nd quarter worth $577,000. Goldman Sachs Group Inc. grew its holdings in shares of SiBone by 28.4% in the first quarter. Goldman Sachs Group Inc. now owns 379,757 shares of the company’s stock worth $5,328,000 after acquiring an additional 83,919 shares during the period. Trexquant Investment LP grew its holdings in shares of SiBone by 31.1% in the first quarter. Trexquant Investment LP now owns 115,114 shares of the company’s stock worth $1,615,000 after acquiring an additional 27,331 shares during the period. Finally, Peregrine Capital Management LLC purchased a new stake in SiBone during the second quarter valued at $6,664,000. Hedge funds and other institutional investors own 98.11% of the company’s stock.

SiBone Stock Performance

SIBN opened at $19.49 on Tuesday. The company has a 50 day simple moving average of $15.67 and a two-hundred day simple moving average of $16.79. The company has a debt-to-equity ratio of 0.21, a current ratio of 7.97 and a quick ratio of 6.62. The firm has a market cap of $845.67 million, a P/E ratio of -38.22 and a beta of 0.81. SiBone has a 1-year low of $12.49 and a 1-year high of $20.05.

SiBone (NASDAQ:SIBN) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.05. The firm had revenue of $48.66 million for the quarter, compared to the consensus estimate of $46.67 million. SiBone had a negative net margin of 11.24% and a negative return on equity of 12.86%. SiBone has set its FY 2025 guidance at EPS. Equities analysts forecast that SiBone will post -0.78 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Anthony J. Recupero sold 3,833 shares of SiBone stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $17.44, for a total transaction of $66,847.52. Following the sale, the insider owned 268,144 shares of the company’s stock, valued at approximately $4,676,431.36. This trade represents a 1.41% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Anshul Maheshwari sold 3,460 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $17.43, for a total value of $60,307.80. Following the completion of the transaction, the chief financial officer directly owned 205,073 shares in the company, valued at approximately $3,574,422.39. This represents a 1.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 125,428 shares of company stock valued at $2,277,640. Insiders own 3.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on SIBN. Truist Financial dropped their target price on SiBone from $22.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, October 15th. Wall Street Zen cut shares of SiBone from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of SiBone in a report on Wednesday, November 19th. Finally, Cantor Fitzgerald set a $25.00 target price on shares of SiBone and gave the company an “overweight” rating in a research report on Monday, August 11th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $23.00.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.